Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Actinium Pharmaceuticals (ATNM) Return on Sales (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Return on Sales for 4 consecutive years, with 1073.69% as the latest value for Q2 2023.

  • On a quarterly basis, Return on Sales fell 89924.0% to 1073.69% in Q2 2023 year-over-year; TTM through Jun 2023 was 1073.69%, a 103789.0% decrease, with the full-year FY2023 number at 602.69%, down 56958.0% from a year prior.
  • Return on Sales was 1073.69% for Q2 2023 at Actinium Pharmaceuticals, down from 450.27% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 5.49% in Q1 2022 to a low of 1084.71% in Q4 2021.
  • A 3-year average of 309.5% and a median of 103.78% in 2022 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: skyrocketed 105160bps in 2022, then crashed -89924bps in 2023.
  • Actinium Pharmaceuticals' Return on Sales stood at 1084.71% in 2021, then soared by 97bps to 33.11% in 2022, then plummeted by -3143bps to 1073.69% in 2023.
  • Per Business Quant, the three most recent readings for ATNM's Return on Sales are 1073.69% (Q2 2023), 450.27% (Q1 2023), and 33.11% (Q4 2022).